Recent Updates
Recently added Catalysts

PTC518

Phase 2

Huntington Disease | Small molecule | Rare Disease |PTC Therapeutics, Inc.|Last Updated: Jan 13, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment159
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT05358717A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)PHASE2 COMPLETED 159Jun 3, 2022Jul 31, 2025Jan 13, 202628 United States, Australia +9
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Baseline up to Month 18

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A TEAE was defined as an AE that had an onset date or date of worsening on or after the first dose of study drug. A summary of other non-serious AEs and all serious adverse events (SAEs), regardless of causality is located in the 'Reported AE section'.

Percent Change From Baseline in Geometric Mean Blood tHTT Protein at Month 3
Baseline, Month 3

Least square (LS) mean and 95% confidence interval (CI) were calculated using mixed-model repeated measures (MMRM). The blood tHTT protein value was log-transformed before fitting the MMRM model. The LS means from MMRM model were back-transformed to present geometric mean percent changes.

Secondary Endpoints
Percent Change From Baseline in Caudate Volume as Assessed Via Volumetric Magnetic Resonance Imaging (vMRI) at Month 12
Baseline, Month 12
Change From Baseline in Composite Unified Huntington's Disease Rating Scale (cUHDRS) Scores at Month 12
Baseline, Month 12
Percent Change From Baseline in Geometric Mean Blood tHTT Protein at Month 12
Baseline, Month 12
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
PTC518 5 mgEXPERIMENTALParticipants will receive PTC518 5 milligrams (mg) tablets once daily orally for 12 months.
PTC518 10 mgEXPERIMENTALParticipants will receive PTC518 10 mg tablets once daily orally for 12 months.
PTC518 20 mgEXPERIMENTALParticipants will receive PTC518 20 mg tablets once daily orally for 12 months.
PlaceboPLACEBO_COMPARATORParticipants will receive placebo matching to PTC518 tablets once daily orally for 12 months.
Interventions
NameTypeDescription
PTC518DRUGPTC518 will be administered per dose and schedule specified in the arm.
PlaceboDRUGPlacebo matching to PTC518 will be administered per schedule specified in the arm.
Unlock Study Design Details
Eligibility Criteria
Age Range25 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites28

Key Inclusion Criteria: * Genetically confirmed HD diagnosis with a cytosine-adenine-guanine (CAG) repeat length from 40 to 50, inclusive Eligibility for HD-ISS Stage 2 Group (Parts A, B, and C): * A Unified Huntington's Disease Rating Scale (UHDRS)-Independence Scale (IS) score of 100 * A UHDRS ...

Countries:United StatesAustraliaAustriaCanadaFranceGermanyItalyNetherlandsNew ZealandSpainUnited Kingdom
Unlock Eligibility Criteria
Competitive Landscape -Huntington's Disease 9 trials